从新鲜和冷冻实体瘤标本中优化细胞核分离，用于多组学测序

Executive Industry Relevance

Optimized nuclei isolation from solid tumor specimens is critical for generating high-quality multiome sequencing data, directly impacting the reliability of tumor heterogeneity analyses in translational oncology. This protocol addresses the challenge of extracting intact nuclei from both fresh and frozen desmoplastic tumor tissues, supporting robust single-cell multiomic profiling. Reliable nuclei preparation at this stage enhances predictive confidence in downstream discovery and biomarker development pipelines.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables high-fidelity interrogation of tumor cell heterogeneity at the single-cell level.
• Supports functional target validation by preserving diverse cell populations during isolation.
• Facilitates mechanistic de-risking through accurate representation of the tumor microenvironment.

Screening & Assay Development

• Provides standardized nuclei preparations for reproducible multiome sequencing assays.
• Ensures quantitative and qualitative consistency in input material for downstream workflows.
• Improves assay readiness by accommodating both fresh and cryopreserved tumor samples.

Translational & Preclinical Research

• Aligns with translational biomarker discovery by enabling paired RNA and chromatin accessibility profiling.
• Maintains disease relevance by capturing the complexity of solid tumor microenvironments.
• Supports continuity from discovery through preclinical validation by standardizing input quality.

Pipeline & Workflow Integration

This nuclei isolation protocol is positioned at the interface of tissue processing and multiomic data generation, bridging early discovery and translational research workflows.

• Discovery Biology: Maximizes hypothesis testing power by preserving cell diversity and integrity.
• Screening: Delivers reproducible, high-quality nuclei for scalable multiome sequencing assays.
• Analytics: Enables robust quantitative readouts for comparing tumor cell states and chromatin landscapes.
• Translational Research: Facilitates biomarker alignment by supporting paired single-cell RNA and ATAC-seq analyses.
• Enterprise Reuse: Establishes a standardized, adaptable protocol for diverse solid tumor types and sample conditions.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in tumor biology and target validation studies.
• Operational Value: Enhances reproducibility and scalability across fresh and frozen tumor samples.
• Strategic Value: Reduces risk of data loss or artifact introduction at the sample preparation stage.
• Portfolio Impact: Supports risk-adjusted advancement of oncology discovery and translational programs.

Implementation Considerations

• Requires expertise in tissue dissociation and nuclei handling for optimal yield and quality.
• Demands access to specialized reagents, cell strainers, and quantitative assessment tools.
• Necessitates cross-team standardization of digestion and lysis conditions for reproducibility.
• Must be adapted for varying tumor types and sample sizes, especially for desmoplastic tissues.
• Careful monitoring of nuclear integrity is essential to avoid downstream sequencing artifacts.

Biopharma FAQs